Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
US6972125B2 · kind B2 · utility
3Cited by
10References
45Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 12, 1999 |
| Grant date | Dec 6, 2005 |
| Priority date | — |
| Expiry date | Aug 18, 2019 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to a humanized anti-B7-2 antibody that comprises a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.